CONSOLIDATED ENTITIES - Pulmoquine Therapeutics, Inc. (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Sep. 30, 2021	Apr. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
CONSOLIDATED ENTITIES
Total assets			$ 926,395	$ 999,570
Cash balance			201,525	246,487
Total operating expenses			16,763	15,671	$ 14,656
Pulmoquine Therapeutics, Inc.
CONSOLIDATED ENTITIES
Proceeds from net distribution on dissolution of Pulmoquine	$ 2,400
Total assets			0	3,500
Net loss			500	2,200
Total operating expenses			$ 700	$ 2,000
Pulmoquine Therapeutics, Inc. | Series A preferred stock
CONSOLIDATED ENTITIES
Securities to be purchased		5,808,550
Securities Purchase Agreement, Amount		$ 5,000